Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit

2016-09-22 21:08:21 | BioPortfolio


This trial is collaboration between Mayo Clinic, Second Opinion Health (Simon Bloch, 408-981-3814) and Allergan. Mayo Clinic investigators are conducting the clinical trial, Second Opinion Health is providing the software for use in the trial (Migraine Alert app for data collection, analysis and machine learning algorithms), and Allergan is providing funding.

The investigators hypothesize that the use of a mobile phone app and Fitbit wearable to collect daily headache diary data, exposure/trigger data and physiologic data will predict the occurrence of migraine attacks with high accuracy. The objective of the trial is to assess the ability to use daily exposure/trigger and symptom data, as well as physiologic data (collected by Fitbit) to create individual predictive migraine models to accurately predict migraine attacks in individual patients via a mobile phone app.


Eliminating migraine attacks before they start is of an enormous importance to migraine sufferers. But figuring out the onset of an attack before it actually starts remains a major challenge for the medical community.

The widespread use of mobile smartphones, the availability of wearable devices that measure health information, and advances in multivariate pattern analysis via machine learning algorithms allow for development of individual predictive models that can determine the likelihood of an individual patient developing a migraine on a given day. Such models are based upon objectively measured biometric parameters (e.g. activity, sleep), objectively measured environmental conditions (e.g. weather parameters), exposures to possible migraine triggers, and patient reported symptoms. Using machine-learning algorithms to explore this large dataset that is collected for each patient, the optimal combination of factors that most accurately predict the likelihood of a migraine attack is determined.

Prediction of individual migraine attacks would have substantial positive impacts for patients with migraine. Accurate prediction of a migraine attack would give the migraineur a greater sense of control over their condition, a sense of control that is often lacking in patients with migraine. Most importantly, if individual migraine attacks could be predicted with high accuracy, treatment of that inevitable migraine attack before development of symptoms could prevent the attack altogether.

Eligible subjects will enter a baseline phase during which subjects will wear a Fitbit device and record data into the daily headache diary using the mobile phone app. This phase will be of variable duration for each subject to a maximum of 75 days. It is during the baseline phase that the individualized predictive model for a migraine attack is developed and optimized.

During the second phase (75 days), the accuracy of the predictive model will be tested. The probability of developing a migraine will be calculated and the accuracy of the prediction will be tested against the patient reported incidence of migraine attacks within the mobile phone app. Subjects will be blinded to the app's migraine attack predictions to avoid expectancy bias.

Migraine prediction suffers from 'the curse of dimensionality' (machine learning parlance). Too many factors affect outcomes, but the outcomes (positive migraine attacks) are few and far in between. To develop an accurate machine learning model using traditional approaches requires a long and impractical time duration. Migraine Alert has effectively addressed these using proprietary algorithms and techniques that generate individual models using fewer migraines. Covariate analysis is performed for each individual using features derived from the raw data. Individual models may differ from one other in the specific feature they use and/or the importance attached to them in the model. Proprietary techniques are used to create these individual models and to monitor their pre-validation and post-validation accuracy and recall. Concept drift as evidenced by any degradation in accuracy or recall is monitored in the prediction phase and model is retrained as necessary.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Migraine Disorders


Migraine Alert App Forecast along with Fitbit wearable


Mayo Clinic Arizona
United States


Enrolling by invitation


Second Opinion Health

Results (where available)

View Results


Published on BioPortfolio: 2016-09-22T21:08:21-0400

Clinical Trials [434 Associated Clinical Trials listed on BioPortfolio]

DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study

The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks. Migraine patie...

A Study of Gastric Delay in Migraine Patients

A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.

Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)

The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.

Nutritional Intervention in Migraine

Migraine is a common medical condition. Several studies suggest that obesity and/or weight gain are risk factors for aggravating migraine course, especially increase the frequency of heada...

Abortive Effect of an Ear Insufflator on Migraine

Evaluate the effectiveness of air insufflation in aborting (stopping) an acute episode of migraine: the insufflation will be used when the subject is experiencing an acute episode of migra...

PubMed Articles [636 Associated PubMed Articles listed on BioPortfolio]

Experience of Surgical Treatment for Occipital Migraine in Taiwan.

Refractory migraine surgery developed since 2003 has excellent results over the past 10 years. According to the pioneer of migraine surgery, Dr. Bahman Guyuron, 5 major surgical classifications of mig...

The migraine postdrome.

Migraine is a common, disabling neurological disorder that affects up to 12% of the world population. Its pathophysiology is incompletely described. Of the various phases of migraine, the migraine pos...

Genetic studies of Polish migraine patients: screening for causative mutations in four migraine-associated genes.

Migraine is the most common neurological disorder, affecting approximately 12 % of the adult population worldwide, caused by both environmental and genetic factors. Three causative genes have been id...

Managing Migraine Headaches in Children and Adolescents.

The diagnosis and management of migraine headaches can be challenging in children and adolescents. The description of migraine in this population may include symptoms that are not typically described ...

Prevalence, Associated Factors, and Impact on Quality of Life of Migraine in a Community in Northeast China.

To validate the Chinese version of the Identification of Migraine screener (ID-Migraine), assess migraine prevalence, identify potential associated factors, and assess the impact of migraine on qualit...

Medical and Biotech [MESH] Definitions

A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Serotonin antagonist used against MIGRAINE DISORDERS and vascular headaches.

A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

More From BioPortfolio on "Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Searches Linking to this Trial